ARMGO Pharma Enrolls First Patient in Phase 2 Trial of ARM210 for the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia

FHS
July 21, 2023
11:04 am

Trial to investigate the safety and efficacy of ARM210 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT).

Cellular Origins, Fresenius Kabi sign development agreement for scalable automation of cell and gene therapy manufacturing

Cellular Origins and Fresenius Kabi, an operating company of Fresenius, announce today they have signed a development agreement that leverages each company’s expertise in cell

October 16, 2024

Early detection key to beating ovarian cancer

‘Symptom triggered testing’, prompted by symptoms such as pain, abdominal bloating/swelling, and feeling full soon after starting to eat, can pick up early stage aggressive

August 14, 2024

Flu season is approaching, CDC says

Flu activity in many parts of the United States is starting to rise more rapidly, signaling that flu season is on the horizon, the Centers

November 17, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.